Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | CETP | P11597 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539823 | 0.90 | MAPK1 (0.63) | TSHRCETPMAPK1HTTALDH1A1 | |
| SCHEMBL4883127 | 0.87 | TSHR (0.62) | TSHRCETPPOLBATML3MBTL1 | |
| SCHEMBL9372218 | 0.86 | TSHR (1.00) | TSHRCETPPOLBATML3MBTL1 | |
| SCHEMBL4092413 | 0.83 | TSHR (0.53) | TSHRL3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL30738431 | 0.79 | HDAC3 (0.73) | TSHRCETPPOLBATML3MBTL1 | |
| SCHEMBL6694932 | 0.79 | HDAC3 (0.73) | TSHRCETPPOLBATML3MBTL1 | |
| SCHEMBL26645943 | 0.79 | HDAC3 (0.77) | TSHRCETPPOLBATML3MBTL1 | |
| SCHEMBL13263765 | 0.79 | CETP (0.67) | TSHRCETPPOLBATML3MBTL1 | |
| SCHEMBL5878480 | 0.78 | CETP (0.77) | TSHRCETPSOAT1MAPK1HDAC3 | |
| SCHEMBL9395051 | 0.78 | CETP (0.77) | TSHRCETPSOAT1MAPK1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445516-B2 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| CN-100473383-C | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMA CO LTD (JP) | 2009-04-01 | — | — | CN | disclosed |
| EP-1708705-B1 | USE OF PIPERIDINE DERIVATIVES FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMA CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| CN-1905877-A | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMA CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1708705-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005072734-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | WO | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | FLT1, FLT4, KDR | TSHR 4330/4885CETP 1881/4885POLB 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.